Gilead’s partnership with generic manufacturers to lower the cost of its HIV drug lenacapavir is criticized for being too restrictive. Key countries with rising HIV rates are excluded, and the control over the active pharmaceutical ingredient could delay price reductions. Patient groups are challenging Gilead’s patents globally, fearing the VL aims to maintain the company’s monopoly.
Related Posts
Nikhil Kamath’s Zerodha launches ‘privacy mode’ feature on Kite to prevent overtrading and protect user data
Zerodha introduces Privacy Mode on its trading platform, Kite, to help users secure sensitive information and discourage overtrading. The feature hides real-time Profit and Loss […]
Taiwan to assist companies relocating from China following Trump tariffs
Taiwan plans to help its companies move production out of China amid concerns over potential US tariffs. The move comes after US president-elect Donald Trump […]
RBI announces final redemption price of Sovereign Gold Bond 2016-17 Series IV
- staff
- March 17, 2025
- 0
The RBI has announced the final redemption price for the Sovereign Gold Bond (SGB) 2016-17 Series IV at Rs 8,634 per gram. Issued in March […]